Latest News & Features
Americas
Hedge fund manager Kyle Bass has been dealt a blow after failing to invalidate two patents owned by biotechnology company Acorda Therapeutics. 25 August 2015
Americas
Sandoz, Allergan and Accord Healthcare have demonstrated “clear and convincing” evidence that a patent owned by Millennium Pharmaceuticals and used in its Velcade cancer treatment drug is invalid, according to a US court ruling. 24 August 2015
Asia
The Indian government has rejected a request by local company Lee Pharma to issue a compulsory licence for AstraZeneca’s diabetes drug Onglyza. 24 August 2015
Americas
Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria. 20 August 2015
Americas
A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies. 20 August 2015
Americas
Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection. 19 August 2015
Americas
Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal. 18 August 2015
Americas
US hedge fund Ferrum Ferro Capital has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint. 17 August 2015
Americas
Law firm Dechert has hired Andrea Reid as partner to the firm’s intellectual property practice in Boston. 14 August 2015
Americas
Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing. 13 August 2015